Follow up of the phase 3 RESPONSE trial of ruxolitinib in polycythemia vera | Prof Jean-Jacques Kiladjian at Annual Meeting 2015 - 101271

Spotlight
Video

Follow up of the phase 3 RESPONSE trial of ruxolitinib in polycythemia vera | Prof Jean-Jacques Kiladjian at Annual Meeting 2015

EMJ has 458 videos Subscribe Here

Loading........
Description: At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Université Paris Diderot Paris, France, discusses follow-up data of the RESPONSE trial, which is a multicentre, open-label phase 3 study evaluating the efficacy and safety of ruxolitinib compared with best available therapy in patients with polycythemia vera resistant to or intolerant of hydroxyurea.

–––

European Medical Journal

Website: http://emjreviews.com/...
Twitter: https://twitter.com/EMJRevi...
Facebook: https://www.facebook.com/em...
Shared By : EMJ
Posted on : 06/22/15
Added : 3 years ago



Recommended

Nothing found.

More From EMJ

Nothing found.